GRCE: Grace Therapeutics Inc Market Capitalization-to-Revenue Ratio
Grace Therapeutics, Inc. (GRCE) develops drugs for rare neurological pathologies, expanding its distribution in Europe and the US. The development of CNS drugs relies on automated synthesis and algorithms. This GURU.Markets chart includes a price/sales multiple level, where captures the current state of the parameter. Stable demand for biotechnology makes the asset a defensive asset, isolating it from global recessions.
Metric breakdowns and analytics for gracetx.com (GRCE)
- stock quotes and analyst forecast:
- market capitalization information:
- book capitalization indicators:
- debt obligations and liquidity statistics:
Total Debt to Capital Grace Therapeutics, Inc.|GRCE - Long-Term Debt to Equity|Current Liabilities to Equity Grace Therapeutics|GRCE - Company Aggregate Debts|Debts to Book Value Grace Therapeutics, Inc.|GRCE - Company Long-Term Liabilities|Company Short-Term Debts Grace Therapeutics|Intermediate Liquidity Ratio gracetx.com
- earnings and multiples data:
GRCE - Net Profit|Company Profit Forecast Grace Therapeutics, Inc.|GRCE - P/E Multiple|Projected Price to Earnings Grace Therapeutics Inc|GRCE - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Grace Therapeutics, Inc.|GRCE - Operating profit before deduction of amortization|Earnings per share for the trailing year Grace Therapeutics|GRCE - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months gracetx.com|GRCE - Earnings per share growth in current year|Projected earnings per share growth rate for next year Grace Therapeutics, Inc.
- total revenue and sales volume data:
General company analysis:GRCE - gracetx.com
Grace Therapeutics, Inc. (GRCE) is optimizing costs by outsourcing clinical development to external partners to mitigate operational risks. The price-to-sales ratio quantifies the efficiency of this virtual model from the investors' perspective. This metric measures the cost of one dollar of revenue, making it possible to identify asset overvaluation relative to industry peers. The P/S ratio dynamics for Grace Therapeutics, Inc. (GRCE) help determine entry points by filtering out the impact of short-term market volatility.
Who Grace Therapeutics, Inc. competes with
BIIB (Biogen) - Market Capitalization-to-Revenue Ratio|P/S Multiple NBIX (Neurocrine Corp)|Regencell Bioscience - Price-to-Revenue Ratio|Axsome Therapeutics - P/S Multiple|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Price-to-Revenue Ratio|Price to Sales Viking Therapeutics Inc (VKTX)|SUPN (Supernus Pharma) - P/S Multiple|CPRX: Market Capitalization-to-Revenue Ratio|P/S Multiple DNLI|Price-to-Revenue Coefficient Harmony Biosciences|Biohaven Ltd - Market Cap to Revenue|P/S Multiple Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Market Cap to Revenue|Price-to-Revenue Coefficient Praxis Corp PRAX|AVXL: P/S Multiple|CBLL (ceribell.com) - Price-to-Revenue Ratio|PRTA (Prothena Corporation) - P/S Multiple|Market Cap to Revenue alector.com (ALEC)|Price-to-Revenue Ratio Annexon, Inc. (ANNX)|OMER - Price to Sales|P/S Multiple NGNE (Neurogene Inc)|AC Immune (ACIU) - Price to Sales|Voyager Therapeutics Inc - P/S Multiple|Neumora (NMRA) - Market Cap to Revenue|SCLX: P/S Multiple|TVGN - Price-to-Revenue Coefficient|ACOG (Alpha Cognition Inc) - P/S Multiple|Market Cap to Revenue cogrx.com (CGTX)|Price-to-Revenue Ratio Inhibikase Therapeutics Inc (IKT)|Price-to-Revenue Coefficient Cassava Sciences|P/S Multiple ASRT (Assertio Holdings)|COYA - Market Cap to Revenue|vistagen.com - P/S Multiple|OVID: Price-to-Revenue Ratio|Acumen Pharmaceuticals, Inc (ABOS) - Price-to-Revenue Ratio|CervoMed Inc - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alterity Therapeutics Limited|clene.com (CLNN) - Price-to-Revenue Coefficient|Market Cap to Revenue PEPG (PepGen Inc)|P/S Multiple jupiterneurosciences.com (JUNS)|Price-to-Revenue Ratio Relmada Therapeutics, Inc. RLMD|ANVS: Market Cap to Revenue Ratio|AIFF - Price-to-Revenue Ratio|KLTO (anewmeds.com) - Market Cap to Revenue Ratio|NRSN (NeuroSense Therapeutics Ltd.) - Market Cap to Revenue|revivapharma.com - Market Capitalization-to-Revenue Ratio|MTVA (metaviatx.com) - P/S Multiple|NRXS: Market Capitalization-to-Revenue Ratio|P/S Multiple HSDT|PASG - Price to Sales|P/S Multiple NEUP (Neuphoria Therapeutics)|NERV: Market Cap to Revenue Ratio|ATHA: Market Cap to Revenue|Addex Therapeutics Ltd - Market Cap to Sales Volume|Alzamend Neuro, Inc. (ALZN) - Price-to-Revenue Ratio|CYCN (Cyclerion Therapeutics Inc.) - Price-to-Revenue Ratio|Market Cap to Revenue PTIX|KTTA: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue CRGT (Cortigent Medical)|ATXI (Avenue Therapeutics, Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Brainstorm Cell Therapeutics, Inc. BCLI|Market Capitalization-to-Revenue Ratio CARA|chromocell.com - P/S Multiple|Price-to-Sales Ratio ELYM|ITCI: P/S Multiple|Price to Sales Longboard Pharmaceuticals, Inc. (LBPH)|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGN: Market Capitalization-to-Revenue Ratio|P/S Multiple NRBO|SAGE: Price-to-Sales Ratio|Synaptogenix Inc. - Market Cap to Revenue|Market Cap to Sales Volume TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - P/S Multiple|Anew Medical (WENA) - Market Cap to Revenue|CERE (Cerevel Corp) - Market Cap to Revenue
